Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Conditions
Brief summary
Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is the second leading cause in China and is receiving increasing global attention. Research on HTG-AP has been hindered by the heterogeneity and complexity of the disease, as well as the limitations of prior single-center studies with small sample sizes, inadequate collection of clinical data, lack of sustainable follow-up, and insufficient tools for large-scale data collection, analysis, and biomarker testing. To address these unique challenges and leverage the opportunity to gain a deeper understanding of HTG-AP, the China Hypertriglyceridemia Pancreatitis Study Group (CHPSG) was initiated in April 2023 as a multi-center collaboration. By utilizing the advantages of multi-center studies, such as external validity and larger sample sizes, CHPSG aims to investigate the prevalence, clinical characteristics, natural history, and risk factors of HTG-AP in China. The consortium will also explore the differences between HTG-AP and other etiologies of pancreatitis, with an emphasis on systemic and local complications, recurrence, and long-term quality of life. Through its phased approach, CHPSG seeks to develop targeted strategies for the prevention and treatment of HTG-AP, ultimately improving patient outcomes.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Aged between 18 and 80 years; * Diagnosed with AP based on at least two of the following criteria (1) acute onset of upper abdominal pain; (2) more than three times the upper limit of the normal range of serum lipase or amylase levels; and (3) typical radiological findings of AP on computed tomography (CT), magnetic resonance imaging, or ultrasonography; * HTG with serum triglyceride levels \>500 mg/dL (5.65 mmol/L) during the current AP episode or at admission; * Patients must have good compliance, with the ability and willingness to adhere to study protocols, provide written informed consent, and maintain their current lifestyle during the study period
Exclusion criteria
* History of chronic pancreatitis or pancreatic cancer; * Severe comorbidities such as malignancy, acute myocardial infarction, or extensive cerebral infarction; * Prior use of lipid-lowering medications; * Pregnancy or breastfeeding; * Lack of signed informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of organ dysfunction | 1-2 weeks | Assessment of multi-organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and other complications |
| Clinical outcomes | 1-2 weeks | Hospital length of stay, ICU admission rate, and mortality |
| Incidence of recurrent HTG-AP | 1 year | The recurrence rate within a defined period |
| Risk factors for recurrence | 1 year | Identification of factors such as triglyceride (TG) levels, BMI, diabetes status, medication use, and lifestyle habits. |
Countries
China
Outcome results
None listed